P4 cap modified tetrapeptidyl α-ketoamides as potent HCV NS3 protease inhibitors
- 16 August 2004
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 14 (16) , 4333-4338
- https://doi.org/10.1016/j.bmcl.2004.05.078
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Pyrrolidine-5,5-trans-lactams. 5. Pharmacokinetic Optimization of Inhibitors of Hepatitis C Virus NS3/4A ProteaseOrganic Letters, 2003
- The design of potent, non-peptidic inhibitors of hepatitis C proteaseEuropean Journal of Medicinal Chemistry, 2003
- Macrocyclic Inhibitors of the NS3 Protease as Potential Therapeutic Agents of Hepatitis C Virus InfectionAngewandte Chemie International Edition in English, 2003
- Hepatitis C Virus Therapies: Current Treatments, Targets and Future PerspectivesAntiviral Chemistry and Chemotherapy, 2003
- Hepatitis C therapeutics: current status and emerging strategiesNature Reviews Drug Discovery, 2002
- 5 Inhibitors of Hepatitis C Virus NS3•4A Protease: An Overdue Line of TherapyProgress in Medicinal Chemistry, 2002
- Emerging therapies for hepatitis C virus infectionEmerging Drugs, 2001
- α-Ketoamides, α-ketoesters and α-diketones as HCV NS3 protease inhibitorsBioorganic & Medicinal Chemistry Letters, 2000
- Hepatitis C virus NS3/4A proteaseAntiviral Research, 1998
- Molecular Targets in Inhibition of Hepatitis C Virus ReplicationAntiviral Chemistry and Chemotherapy, 1997